News: KZA Kazia Therapeutics Reports Promising Interim Data From Combination Study Of Paxalisib...

Aug 5 (Reuters) - Kazia Therapeutics Ltd (KZA) :

• KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES
• KAZIA THERAPEUTICS LTD- INTERIM DATA FROM THE FIRST STAGE OF STUDY REPORTS THAT ALL 9 EVALUABLE PATIENTS EXPERIENCED COMPLETE OR PARTIAL RESPONSE
• KAZIA THERAPEUTICS LTD- SAFETY PROFILE OF PAXALISIB IN COMBINATION WAS BROADLY CONSISTENT WITH MONOTHERAPY EXPERIENCE IN OTHER CLINICAL TRIALS
• KAZIA THERAPEUTICS LTD- RECRUITMENT TO THE EXPANSION STAGE HAS ALREADY COMMENCED, WITH THE OBJECTIVE OF RECRUITING AN ADDITIONAL 12 PATIENTS
• KAZIA THERAPEUTICS- ENROLMENT TO SECOND STAGE OF STUDY IS UNDERWAY, ESTIMATE PRELIMINARY DATA FROM SECOND PART OF PHASE I CLINICAL TRIAL IN CY2023

(([email protected];))